Skip to main content
Clinical Trials/NCT02839278
NCT02839278
Completed
Not Applicable

Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases

Centre Hospitalier Universitaire de Besancon1 site in 1 country150 target enrollmentApril 2015
ConditionsInflammation
InterventionsBlood sample

Overview

Phase
Not Applicable
Intervention
Blood sample
Conditions
Inflammation
Sponsor
Centre Hospitalier Universitaire de Besancon
Enrollment
150
Locations
1
Primary Endpoint
Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim of the study is to investigate in vitro the impact of a novel anti-inflammatory treatment on costimulatory molecules expressed on monocytes.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
September 2, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Immune-mediated inflammatory disease (non-ST segment elevation myocardial infarction, Rheumatoid arthritis, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Crohn's disease, Ulcerative colitis, Cystic fibrosis, Psoriasis, Multiple sclerosis or major depressive episode)
  • Patient able to understand the reason of the study
  • Patient not opposed to the conservation of biological samples for scientific research

Exclusion Criteria

  • Pregnant woman
  • Subject without health insurance

Arms & Interventions

Immune-mediated inflammatory disease

Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).

Intervention: Blood sample

Outcomes

Primary Outcomes

Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes

Time Frame: 24 months

Study Sites (1)

Loading locations...

Similar Trials